mtm laboratories AG is developing and manufacturing detection technologies for cervical cancer based on the p16 biomarker.


Worldwide, cervical cancer is the second most common cancer in women. Identifying CIN (Cervical Intraepithelial Neoplasia) early is a critical component to a good prognosis, which is the reason why early detection is so important for cervical cancer. mtm's CINtec^® technology, based on the detection of a specific cellular biomarker p16 (p16^INK4a with the proprietary E6H4™ clone), offers the potential for highly specific and accurate diagnosis of even symptomless early stage cervical cancer. mtm is currently marketing CINtec^® Histology and CINtec^® Cytology as adjunctive tools for the early detection of cervical cancer. In addition, mtm is developing a further advanced version to detect p16 the Cervatec^® ELISA Assay.

mtm is ISO 9001 and 13485 certified and operates on a global basis with headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain.

mtm dedicates its work and efforts to improving women's health.